These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36610002)

  • 41. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML.
    Narayanan D; Pozdnyakova O; Hasserjian RP; Patel SS; Weinberg OK
    Blood Adv; 2021 Jun; 5(11):2539-2549. PubMed ID: 34100902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
    Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
    Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.
    Suzuki R; Onizuka M; Kojima M; Shimada M; Okamura K; Fukagawa S; Tsuboi K; Kikuchi A; Kobayashi H; Shintani A; Ogawa Y; Kawada H; Hotta T; Ando K
    Int J Hematol; 2007 Dec; 86(5):422-8. PubMed ID: 18192111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
    Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
    Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
    Dunlap JB; Leonard J; Rosenberg M; Cook R; Press R; Fan G; Raess PW; Druker BJ; Traer E
    Am J Hematol; 2019 Aug; 94(8):913-920. PubMed ID: 31145495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
    Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
    J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Significance of NPM1 Gene Mutations in AML.
    Hindley A; Catherwood MA; McMullin MF; Mills KI
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
    Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
    Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chromosomal Abnormalities and Prognosis in
    Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
    J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
    Patel JP; Gönen M; Figueroa ME; Fernandez H; Sun Z; Racevskis J; Van Vlierberghe P; Dolgalev I; Thomas S; Aminova O; Huberman K; Cheng J; Viale A; Socci ND; Heguy A; Cherry A; Vance G; Higgins RR; Ketterling RP; Gallagher RE; Litzow M; van den Brink MR; Lazarus HM; Rowe JM; Luger S; Ferrando A; Paietta E; Tallman MS; Melnick A; Abdel-Wahab O; Levine RL
    N Engl J Med; 2012 Mar; 366(12):1079-89. PubMed ID: 22417203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
    Schnittger S; Schoch C; Kern W; Mecucci C; Tschulik C; Martelli MF; Haferlach T; Hiddemann W; Falini B
    Blood; 2005 Dec; 106(12):3733-9. PubMed ID: 16076867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated
    Memoli M; Genthon A; Favale F; Lapusan S; Johnson N; Adaeva R; Deswarte C; Battipaglia G; Malard F; Duléry R; Brissot E; Banet A; Van de Wyngaert Z; Mohty M; Delhommeau F; Legrand O; Hirsch P
    Leuk Lymphoma; 2022 Sep; 63(9):2171-2179. PubMed ID: 35459427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
    Verhaak RG; Goudswaard CS; van Putten W; Bijl MA; Sanders MA; Hugens W; Uitterlinden AG; Erpelinck CA; Delwel R; Löwenberg B; Valk PJ
    Blood; 2005 Dec; 106(12):3747-54. PubMed ID: 16109776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia.
    Chen X; Tian C; Hao Z; Pan L; Hong M; Wei W; Muyey DM; Wang H; Chen X
    Cancer Med; 2023 May; 12(9):10340-10350. PubMed ID: 36912186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.